Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia

Background.Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in infants. MEDI-493(palivizumab) is a humanized monoclonal antibody to the fusion protein of RSV and is active in animal models for prevention of pulmonary RSV replication.Objective.To describ